Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women

Fertility and Sterility

Volumn 71, Issue 4, 1999, Pages 663-670

  Van Baal, W Marchien ^a   Kenemans, Peter ^a   Emeis, Jef J ^b   Schalkwijk, Casper G ^a   Mijatovic, Velja ^a   Van Der Mooren, Marius J ^a   Vischer, Ulrich M ^c   Stehouwer, Coen D A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

E selectin; Endothelial function; Endothelin 1; Estrogen; Fibrinogen; Hormone replacement therapy; Inflammatory activity; Postmenopausal; Thrombomodulin; Von Willebrand factor

Indexed keywords

BIOCHEMICAL MARKER; C REACTIVE PROTEIN; DYDROGESTERONE; DYDROGESTERONE PLUS ESTRADIOL; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN 1; ESTROGEN; FIBRINOGEN; GLYCERYL TRINITRATE; THROMBOMODULIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD CLOTTING; BRACHIAL ARTERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FIBRINOGEN BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; LONG TERM CARE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASCULAR ENDOTHELIUM; VASODILATATION;

DYDROGESTERONE; E-SELECTIN; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; FIBRINOGEN; HUMANS; INFLAMMATION; MIDDLE AGED; POSTMENOPAUSE; PROSPECTIVE STUDIES; SOLUBILITY; THROMBOMODULIN; VON WILLEBRAND FACTOR;

EID: 0032981919     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(98)00513-5     Document Type: Article

References (53)

1. Pines A., Mijatovic V., van der Mooren M.J., Kenemans P. Hormone replacement therapy and cardioprotection: basic concepts and clinical considerations. Eur J Obstet Gynecol Reprod Biol. 71:1997;193-197.
2. Ciceneli E., Ignarro L.J., Lograno M., Matteo G., Falco N., Schonauer L.M. Acute effects of transdermal estradiol administration on plasma levels of nitric oxide in postmenopausal women. Fertil Steril. 67:1997;63-66.
3. Krasinski K., Spyridopoulos I., Asahara T., Zee van der R., Isner J.M., Losordo D.W. Estradiol accelerates functional endothelial recovery after arterial injury. Circulation. 95:1997;1768-1772.
4. Wilcox J.G., Hatch I.E., Gentzschein E., Stanczyk F.Z., Lobo R.A. Endothelin levels decrease after oral and non-oral estrogen in postmenopausal women with increased cardiovascular risk factors. Fertil Steril. 67:1997;273-277.
5. Mikkola T., Viinikka L., Ylikorkala O. Estrogen and postmenopausal estrogen/progestagen therapy - effect on endothelium-dependent prostacyclin, nitric oxide and endothelin-1 production. Eur J Obstet Gynecol Reprod Biol. 79:1998;75-82.
6. Stehouwer C.D.A., Lambert J., Donker A.J.M., Hinsbergh V.W.M. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res. 34:1997;55-68.
7. Thompson S.G., Kienast J., Pyke S.D.M., Haverkate F., van de Loo J.C.W. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med. 332:1995;635-641.
8. Badimon L.J.J., Chesebro J.H., Fuster V. Von Willebrand factor and cardiovascular disease. Thromb Haemost. 70:1993;111-118.
9. Omland O., Aakvaag R. Plasma endothelin determination as a prognostic indicator of 1 year mortality after acute myocardial infarction. Circulation. 89:1994;1573-1579.
10. Blann A.D., Amiral J., McCollum C.N. Prognostic value of increased soluble thrombomodulin and increased E-selectin in ischemic heart disease. Eur J Haematol. 59:1997;115-120.
11. Blann A.D., Miller J.P., Mccollum C.N. Von Willebrand factor and soluble E-selectin in the prediction of cardiovascular diseases progression in hyperlipidaemia. Atherosclerosis. 132:1997;151-156.
12. Haverkate F., Thompson S.G., Pepys M.B. C-reactive protein and cardiovascular disease. Fibrinolysis Proteolysis. 11:(Suppl 1):1997;133-134.
13. Salomaa V., Rasi V., Pekkanen J., Vahtera E., Jauhiainen M., Vartiainen E., et al. Association of hormone replacement therapy with hemostatic and other cardiovascular risk factors - The Finnish hemostasis study. Arterioscler Thromb Vasc Biol. 15:1995;1549-1555.
14. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.M., Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 336:1997;973-979.
15. Frohlich M., Schunkert H., Hense H.W., Tropitzch A., Hendricks P., Doring A., et al. Effects of hormone replacement therapies on fibrinogen and plasma viscosity in postmenopausal women. Br J Haematol. 100:1998;577-581.
16. Lieberman E.H., Gerhard M.D., Uehata A., Walsh B.W., Selwyn A.P., Ganz P., et al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med. 121:1994;936-941.
17. Imthurn B., Rosselli M., Jaeger A.W., Keller P.J., Dubey R.K. Differential effects of hormone replacement therapy on endogenous nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17-beta-estradiol valerate and cyproterone acetate or medroxyprogesterone acetate. J Clin Endocrinol Metab. 82:1997;388-394.
18. Pinto S., Virdis A., Ghiadoni L. Endogenous estrogen and acetylcholine-induced vasodilatation in normotensive women. Hypertension. 29:1997;268-273.
19. Polderman K.H., Stehouwer C.D.A., van Kamp G.J., Dekker G.A., Verheugt F.W.A., Gooren L.J.G. Influence of sex hormones on plasma endothelin levels. Ann Intern Med. 118:1993;429-432.
20. McCrohon J.A., Adams M.R., McCredie R.J., Robinson J., Pike A., Abbey M., et al. Hormone replacement therapy is associated with improved arterial physiology in healthy post-menopausal women. Clin Endocrinol (Oxf). 45:1996;435-441.
21. Ylikorkala O., Cacciatore B., Paakkari I. The long-term effects of oral and transdermal postmenopausal hormone replacement therapy on nitric oxide, endothelin-1, prostacyclin, and thromboxane. Fertil Steril. 69:1998;883-888.
22. Rosselli M., Imthurn B., Keller P.J., Jackson E.K., Dubey R.K. Circulating nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17 beta-estradiol and norethisterone acetate. A two-year follow-up study. Hypertension. 25:1995;848-853.
23. Sorensen K.E., Dorup I., Hermann A.P., Mosekilde L. Combined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function. Circulation. 97:1998;1234-1238.
24. Chen F.P., Lee N., Wang C.H., Cherng W.J., Soong Y.K. Effects of hormone replacement therapy on cardiovascular risk factors in postmenopausal women. Fertil Steril. 69:1998;267-273.
25. van Kesteren P.J.M., Kooistra T., Lansink M., van Kamp G.J., Asscheman H., Gooren L.J.G., et al. The effects of sex steroids on plasma levels of marker proteins of endothelial cell functioning. Thromb Haemost. 79:1998;1029-1033.
26. Gevers Leuven J.A., van der Mooren M.J., Buytenhek R. The effect of medrogestone on plasma lipids and lipoproteins in postmenopausal women using conjugated estrogens an open randomized comparative study . Fertil Steril. 6:1995;525-531.
27. Lee A.J., Lowe G.D., Smith W.C., Tunstall-Pedoe H. Plasma fibrinogen in women relationships with oral contraception, the menopause and hormone replacement therapy . Br J Haematol. 83:1993;616-621.
28. Lindoff C., Peterson F., Lecander I., Martinsson G., Astedt B. Transdermal estrogen replacement therapy beneficial effects on hemostatic risk factors for cardiovascular disease . Maturitas. 24:1996;43-50.
29. Effects on haemostasis of hormone replacement therapy with transdermal and oral sequential medroxyprogesterone acetate a 1-year, double-blind, placebo-controlled study . Thromb Haemost. 75:1996;476-480.
30. Effects of estrogen or estrogen/progestin regimes on heart disease risk factors in postmenopausal women the Postmenopausal Estrogen/Progestin Intervention (PEPI) trial . J Am Med Assoc. 273:1995;199-208.
31. Lambert J., Aarsen M., Donker A.J.M., Stehouwer C.D.A. Endothelium-dependent and -independent vasodilatation of large arteries in normoalbuminuric insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol. 16:1996;705-711.
32. Ingerslev J.A. A sensitive ELISA for von Willebrand factor (vWF:Ag). Scand J Clin Lab Invest. 17:1987;237-246.
33. Vischer U.M., Ingerslev J., Wolheim C.B.M., Tsakiris D.A., Heafeli W.E., Kruithof E.K.O. Acute von Willebrand factor secretion from the endothelium in vivo assessment through plasma propeptide (vWF:AgII) levels . Thromb Haemost. 77:1997;387-393.
34. Claus A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des fibrinogens. Acta Haematol. 17:1957;237-246.
35. Myrup B., de Maat M., Rossing P., Gram J., Kluft C., Jespersen J. Elevated fibrinogen and the relation to acute phase response in diabetic nephropathy. Thromb Haemost. 81:1996;485-490.
36. Thomas C.G., van den Berg R.J., Seger M.F.G., Bartelink M.L., Thien T. Inaccurate measurements of 17β-oestradiol in serum of female volunteers after oral administration of milligram amounts of micronised 17β-oestradiol. Clin Chem. 39:1993;2341-2342.
37. Celermajer D.S., Sorensen K.E., Gooch V.M., Spiegelhalter D.J., Miller O.I., Sulivan I.D., et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 340:1992;1111-1115.
38. Anderson T.J., Uehata A., Gerhard M.D., Meredith I.T., Knab S., Delagrange D., et al. Close relationship of endothelial function in human coronary and peripheral circulations. J Am Coll Cardiol. 26:1995;1235-1241.
39. Webb D. Physiological role of endothelin system in human cardiovascular and renal haemodynamics. Curr Opin Nephrol Hypertens. 6:1997;69-73.
40. Ylikorkala O., Orpana A., Puolakka J., Pyorala T., Viinikka L. Postmenopausal hormonal replacement decreases plasma levels of endothelin-1. J Clin Endocrinol Metab. 80:1995;3384-3387.
41. Hashimoto M., Akishita M., Eto M., Ishikawa M., Kozaki K., Toba K., et al. Modulation of endothelium-dependent flow-mediated dilatation of the brachial artery by sex and menstrual cycle. Circulation. 92:1995;3431-3435.
42. Taddei S., Virdis A., Ghiadoni L. Menopause is associated with endothelial dysfunction in women. Hypertension. 28:1996;576-582.
43. Volterrani M., Rosano G., Coats A., Beale C., Collins P. Estrogen acutely increases peripheral blood flow in postmenopausal women. Am J Med. 99:1995;119-122.
44. Gilligan D.M., Badar D.M., Panza J.A., Quyyumi A.A., Cannon R.O. III. Effects of estrogen replacement therapy on peripheral vasomotor function in postmenopausal women. Am J Cardiol. 75:1995;264-268.
45. Gilligan D.M., Badar D.M., Panza J.A., Quyyumi A.A., Cannon R.O. III. Acute vascular effects of estrogen in postmenopausal women. Circulation. 90:1994;786-791.
46. Pigott R., Dillon L.P., Hemingway I.H., Gearing A.J.H. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatant of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun. 187:1992;584-589.
47. Caulin-Glaser T., Watson C.A., Pardi R., Bender J.R. Effects of 17β-oestradiol on cytokine-induced endothelial cell adhesion molecule expression. J Clin Invest. 98:1996;36-42.
48. Sadler J.E. Thrombomodulin structure and function. Thromb Haemost. 78:1997;392-395.
49. Blann A.D., Daly R.J., Amiral J. The influence of age, gender and ABO blood group on soluble endothelial cell markers and adhesion molecules. Br J Haematol. 92:1996;498-500.
50. Nilsson T.K., Hellsten G., Admiral J. Plasma thrombomodulin concentration in relation to cardiovascular risk factors in a population sample. Blood Coagul Fibrinolysis. 4:1993;455-458.
51. Harrison R.L., McKwee P.A. Estrogen stimulates von Willebrand factor production by cultured endothelial cells. Blood. 63:1984;657-664.
52. Holm B., Nilson D.W.T., Kierulf P. Purification and characterization of 3 fibrinogens with different molecular weights obtained from normal human plasma. Thromb Res. 37:1985;165-176.
53. Kockx M, de Maat MPM, Knipscheer HC, Kastelein JJP, Kluft C, Princen HMG, et al. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1, and fibrinogen in hyperlipidaemic patients. Thromb Haemost 1997;78:1176-2.